At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LY2216684 and Fluoxetine Pharmacokinetic Interaction Study in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY2216684 and Fluoxetine for Major Depressive Disorder. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to measure if there is any difference in how the body breaks down or inactivates either fluoxetine or LY2216684 when both of these medicines are given together. This study will look at how fluoxetine might affect LY2216684 and how giving LY2216684 might affect fluoxetine in the body. The duration of study participation in this study is approximately 36 days not including the screening appointment. This study requires 1 research unit confinement of 29 days/28 nights followed by 1 outpatient appointment. A screening appointment is required within 30 days prior to the start of the study.
Study Details
Timeline
Interventions
LY2216684: 18 mg po QD on Days 1, 2, and 3 and Days 25-27
Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)